Paola Di Meglio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3385224/publications.pdf

Version: 2024-02-01

44 papers

5,514 citations

257450 24 h-index 302126 39 g-index

51 all docs

51 docs citations

times ranked

51

8970 citing authors

#	Article	IF	CITATIONS
1	Differences in Clinical Features and Comorbid Burden between HLA-Câ^—06:02 Carrier Groups in >9,000 People with Psoriasis. Journal of Investigative Dermatology, 2022, 142, 1617-1628.e10.	0.7	11
2	Vaccine hesitancy and access to psoriasis care during the ⟨scp⟩COVID⟨ scp⟩ â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.5	11
3	Biomarkers of disease progression in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 481-493.	1.5	22
4	Biomarkers of systemic treatment response in people with psoriasis: a scoping review. British Journal of Dermatology, 2022, 187, 494-506.	1.5	14
5	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	2.9	136
6	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.5	26
7	Defining trajectories of response in patients with psoriasis treated with biologic therapies. British Journal of Dermatology, 2021, 185, 825-835.	1.5	4
8	CYP1A1 Enzymatic Activity Influences Skin Inflammation Via Regulation of the AHR Pathway. Journal of Investigative Dermatology, 2021, 141, 1553-1563.e3.	0.7	34
9	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. Journal of Investigative Dermatology, 2021, 141, 1872-1878.	0.7	4
10	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	2.4	18
11	Guardians of the barrier: Microbiota engage AHR in keratinocytes to maintain skin homeostasis. Cell Host and Microbe, 2021, 29, 1213-1216.	11.0	4
12	Enhanced NF- \hat{l}° B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	12.8	23
13	Exploring the role of immune pathways in the risk and development of depression in adolescence: Research protocol of the IDEA-FLAME study. Brain, Behavior, & Immunity - Health, 2021, 18, 100396.	2.5	1
14	T-cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. Journal of Allergy and Clinical Immunology, 2020, 145, 1021-1025.e15.	2.9	13
15	Global reporting of cases of COVIDâ€19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 2020, 183, 404-406.	1.5	18
16	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2019, 143, 2120-2130.	2.9	128
17	Aldara-induced dermatitis is associated with development of liver fibrosis in mice. British Journal of Dermatology, 2018, 179, 9-10.	1.5	0
18	Immunopathogenesis of Psoriasis. , 2017, , 373-395.		4

#	Article	IF	CITATIONS
19	An analysis of IL-36 signature genes and individuals with $\langle i \rangle$ IL1RL2 $\langle i \rangle$ knockout mutations validates IL-36 as a psoriasis therapeutic target. Science Translational Medicine, 2017, 9, .	12.4	124
20	Psoriasis, Cutaneous Lupus Erithematosus and Immunobiology of the Skin., 2016, , 192-203.		0
21	AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production. Journal of Investigative Dermatology, 2016, 136, 2251-2259.	0.7	128
22	Targeting CD8+ T cells prevents psoriasis development. Journal of Allergy and Clinical Immunology, 2016, 138, 274-276.e6.	2.9	125
23	The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis. Cell, 2015, 161, 387-403.	28.9	292
24	Targeted Therapies and Biomarkers for Personalized Treatment of Psoriasis., 2015,, 77-100.		2
25	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. Journal of Investigative Dermatology, 2014, 134, 1779.	0.7	1
26	The Aryl Hydrocarbon Receptor: Multitasking in the Immune System. Annual Review of Immunology, 2014, 32, 403-432.	21.8	708
27	Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis. Journal of Investigative Dermatology, 2014, 134, 984-991.	0.7	329
28	Psoriasis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015354-a015354.	6.2	233
29	Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions. Immunity, 2014, 40, 989-1001.	14.3	285
30	CD8 T Cells and IFN-Î ³ Emerge as Critical Players for Psoriasis in a Novel Model of Mouse Psoriasiform Skin Inflammation. Journal of Investigative Dermatology, 2013, 133, 871-874.	0.7	19
31	Biomarkers in psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases, 2013, 72, ii104-ii110.	0.9	107
32	The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients. Journal of Investigative Dermatology, 2013, 133, 2381-2389.	0.7	51
33	The Multitasking Organ: Recent Insights into Skin Immune Function. Immunity, 2011, 35, 857-869.	14.3	269
34	The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLoS ONE, 2011, 6, e17160.	2.5	228
35	Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. American Journal of Human Genetics, 2011, 89, 432-437.	6.2	468
36	The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biology Reports, 2010, 2, .	4.0	43

#	Article	IF	CITATIONS
37	The lκB Kinase Inhibitor Nuclear Factor-κB Essential Modulator–Binding Domain Peptide for Inhibition of Injury-Induced Neointimal Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2458-2466.	2.4	26
38	The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis. Journal of Investigative Dermatology, 2009, 129, 1339-1350.	0.7	926
39	A Role for Th17 Cells in the Immunopathogenesis of Atopic Dermatitis?. Journal of Investigative Dermatology, 2008, 128, 2569-2571.	0.7	96
40	Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Human Genetics, 2007, 122, 201-206.	3.8	373
41	Neutralization of Interleukin-18 Inhibits Neointimal Formation in a Rat Model of Vascular Injury. Circulation, 2006, 114, 430-437.	1.6	67
42	Hydroxytyrosol, a phenolic compound from virgin olive oil, prevents macrophage activation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 457-465.	3.0	92
43	A new cytotoxic polychlorinated sulfolipid from contaminated Adriatic mussels. Tetrahedron, 2004, 60, 7093-7098.	1.9	46
44	Cloricromene in endotoxemia: role of NF-κB. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 140-145.	3.0	4